The Oncoguard Liver platform reached an overall sensitivity of 80% and early stage-sensitivity of 72% for HCC diagnosis through a screening for methylation markers (HOXA1, TSPYLS, EMX1, B3GALT6), AFP and AFP-L3% [33]. This evidence concerns the gene EMX1 and hepatocellular carcinoma.